Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05182294 · ClinicalTrials.gov registry record · NA
Tolerance and Acute Effects of a New HFNT Nasal Cannula
A NA study of COPD Exacerbation Acute, sponsored by Temple University.
- Completed
- Registry status
- NA
- Development phase
- 14
- Enrollment target
- 1
- Study location
NCT05182294 is a NA study of COPD Exacerbation Acute that has completed, run by Temple University. The registered enrollment target is 14 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05182294, a NA study of COPD Exacerbation Acute, has completed, sponsored by Temple University.
- COMPLETED
- Registry status
- NA
- Development phase
- 14 participants
- Enrollment target
- 1
- Study location
Study Summary
In the care of patients experiencing an acute exacerbation of COPD, supplemental oxygen therapy is often required. Oxygen is typically administered at flow rates between 1 and 4 liters per minute. High-flow nasal therapy (HFNT) has been reported to have beneficial effects in patients with hypoxemic respiratory failure and in hospitalized and non-hospitalized patients with severe COPD. Clinical efficacy in improving gas exchange depends upon patient tolerance and device-related properties such as flow rate and creation of turbulent flow in the conducting airways to improve oxygenation and carbon dioxide elimination. Alterations of nasal prong structure, such as nasal prong dimensions, may produce more robust turbulent flow at lower flow rates thereby improving gas exchange as well as patient tolerance. In this pilot study we will assess the impact of a new nasal cannula with asymmetric cannula dimensions that may create more turbulent flow at lower flow rates compared to the current symmetric nasal cannula on patient comfort as well as vital signs, pulse oximetry, breathing pattern and parameters of gas exchange in hospitalized patients with a COPD exacerbation.
Conditions Studied
Interventions
- DEVICE AIRVO 2, the new asymmetric nasal cannula
Study Locations (1)
Pennsylvania
- Temple University Hospital - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2022-05-25 |
| Est. Completion | 2023-01-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05182294
The ClinicalTrials.gov registry entry for NCT05182294 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Temple University, which has 163 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with COPD Exacerbation Acute appearing as the primary indexed condition, and to 1 intervention - of which AIRVO 2, the new asymmetric nasal cannula is the first listed.
NCT05182294 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05182294 about?
NCT05182294 is a clinical study titled "Tolerance and Acute Effects of a New HFNT Nasal Cannula". In the care of patients experiencing an acute exacerbation of COPD, supplemental oxygen therapy is often required. Oxygen is typically administered at flow rates between 1 and 4 liters per minute. High-flow nasal therapy (HFNT) has been reported to have beneficial effects in patients with hypoxemic ...
What is the current status of trial NCT05182294?
This trial is currently completed. It is a NA study. The enrollment target is 14 participants. The study started on 2022-05-25. Estimated completion is 2023-01-31.
What conditions does trial NCT05182294 study?
This clinical trial studies the following conditions: COPD Exacerbation Acute.
What interventions are being tested in trial NCT05182294?
The interventions under investigation include: AIRVO 2, the new asymmetric nasal cannula (DEVICE).
Who is sponsoring clinical trial NCT05182294?
This trial is sponsored by Temple University, which has 163 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05182294 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COPD Exacerbation Acute
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.